User login
Alopecia areata (AA) is an autoimmune condition that affects children, adolescents, and adults. Severe AA often causes significant burdens, physical discomfort, and psychological stress. Yet, response to therapy is often unpredictable, running the gamut from being refractory to treatment to spontaneous remission.
Dermatologists Raj Chovatiya from Chicago Medical School and Jason Hawkes from the Pacific Skin Institute discuss how to assess AA severity and appropriate therapies, particularly the evolving landscape of JAK inhibitors for patients with severe AA.
The panelists begin by defining severe AA on the basis of the Severity of Alopecia Tool (SALT) score, which assesses AA severity by percentage of hair loss. A patient who has lost over 50% of scalp hair is considered to have severe AA.
Until recently, traditional therapy for severe AA has relied on injectable and systemic corticosteroids, both of which have drawbacks for patients with severe disease. The emergence of Janus kinase (JAK) inhibitors has offered another option for these patients. The panelists discuss recent clinical trials that have shown promising results from JAK inhibitors for treatment of severe AA.
--
Raj Chovatiya, MD, PhD, MSCI, Clinical Associate Professor, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois; Founder and Director, Center for Medical Dermatology and Immunology Research, Chicago, Illinois
Raj Chovatiya, MD, PhD, MSCI, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; Amgen; Apogee Therapeutics; Arcutis; Argenx; ASLAN Pharmaceuticals; Beiersdorf; Boehringer Ingelheim; Bristol Myers Squibb; Cara Therapeutics; Dermavant; Eli Lilly
Serve(d) as a speaker or a member of a speakers bureau for: AbbVie; Arcutis; Beiersdorf; Boehringer Ingelheim; Bristol Myers Squibb; Dermavant; Eli Lilly and Company; Incyte; LEO Pharma
Alopecia areata (AA) is an autoimmune condition that affects children, adolescents, and adults. Severe AA often causes significant burdens, physical discomfort, and psychological stress. Yet, response to therapy is often unpredictable, running the gamut from being refractory to treatment to spontaneous remission.
Dermatologists Raj Chovatiya from Chicago Medical School and Jason Hawkes from the Pacific Skin Institute discuss how to assess AA severity and appropriate therapies, particularly the evolving landscape of JAK inhibitors for patients with severe AA.
The panelists begin by defining severe AA on the basis of the Severity of Alopecia Tool (SALT) score, which assesses AA severity by percentage of hair loss. A patient who has lost over 50% of scalp hair is considered to have severe AA.
Until recently, traditional therapy for severe AA has relied on injectable and systemic corticosteroids, both of which have drawbacks for patients with severe disease. The emergence of Janus kinase (JAK) inhibitors has offered another option for these patients. The panelists discuss recent clinical trials that have shown promising results from JAK inhibitors for treatment of severe AA.
--
Raj Chovatiya, MD, PhD, MSCI, Clinical Associate Professor, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois; Founder and Director, Center for Medical Dermatology and Immunology Research, Chicago, Illinois
Raj Chovatiya, MD, PhD, MSCI, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; Amgen; Apogee Therapeutics; Arcutis; Argenx; ASLAN Pharmaceuticals; Beiersdorf; Boehringer Ingelheim; Bristol Myers Squibb; Cara Therapeutics; Dermavant; Eli Lilly
Serve(d) as a speaker or a member of a speakers bureau for: AbbVie; Arcutis; Beiersdorf; Boehringer Ingelheim; Bristol Myers Squibb; Dermavant; Eli Lilly and Company; Incyte; LEO Pharma
Alopecia areata (AA) is an autoimmune condition that affects children, adolescents, and adults. Severe AA often causes significant burdens, physical discomfort, and psychological stress. Yet, response to therapy is often unpredictable, running the gamut from being refractory to treatment to spontaneous remission.
Dermatologists Raj Chovatiya from Chicago Medical School and Jason Hawkes from the Pacific Skin Institute discuss how to assess AA severity and appropriate therapies, particularly the evolving landscape of JAK inhibitors for patients with severe AA.
The panelists begin by defining severe AA on the basis of the Severity of Alopecia Tool (SALT) score, which assesses AA severity by percentage of hair loss. A patient who has lost over 50% of scalp hair is considered to have severe AA.
Until recently, traditional therapy for severe AA has relied on injectable and systemic corticosteroids, both of which have drawbacks for patients with severe disease. The emergence of Janus kinase (JAK) inhibitors has offered another option for these patients. The panelists discuss recent clinical trials that have shown promising results from JAK inhibitors for treatment of severe AA.
--
Raj Chovatiya, MD, PhD, MSCI, Clinical Associate Professor, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois; Founder and Director, Center for Medical Dermatology and Immunology Research, Chicago, Illinois
Raj Chovatiya, MD, PhD, MSCI, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; Amgen; Apogee Therapeutics; Arcutis; Argenx; ASLAN Pharmaceuticals; Beiersdorf; Boehringer Ingelheim; Bristol Myers Squibb; Cara Therapeutics; Dermavant; Eli Lilly
Serve(d) as a speaker or a member of a speakers bureau for: AbbVie; Arcutis; Beiersdorf; Boehringer Ingelheim; Bristol Myers Squibb; Dermavant; Eli Lilly and Company; Incyte; LEO Pharma
